An immunocompetent 82-year-old woman developed endocarditis caused by an atypical organism called Achromobacter xylosoxidans, after a first valvular surgery. The intravenous antibiotic therapy with ceftazidime - 2 g every 8 hours during five weeks - a key part of the treatment, induced agranulocytosis as an adverse event. Cross-reactivity between antibiotics was suspected. Finally, the patient's cure was the result of a coordinated effort between medical and surgical professionals. Postoperative follow-up is six years.
Keywords: achromobacter xylosoxidans; adverse drug event; agranulocytosis; mitral endocarditis; mitral valve surgery.
Copyright © 2023, Channaoui et al.